19:22 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Incyte's Jakafi meets in Phase II for steroid-refractory GvHD

Incyte Corp. (NASDAQ:INCY) said Jakafi ruxolitinib in combination with corticosteroids met the primary endpoint in the U.S. Phase II REACH1 trial to treat steroid-refractory acute graft-versus-host disease (GvHD). The company plans to submit an sNDA...
21:38 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; infectious disease

INDICATION: Acute myelogenous leukemia (AML); Candida In vitro, cell culture and mouse studies identified an aminopyrimidine-based dual JAK-2/HDAC6 inhibitor that could help treat AML and Candida albicans infection. Chemical synthesis of aminopyrimidine analogs linked to hydroxamic...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
20:22 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Lilly planning Phase III trials for Olumiant in lupus

Eli Lilly and Co. (NYSE:LLY) said it plans to start this year Phase III testing of Olumiant baricitinib to treat systemic lupus erythematosus (SLE) after reporting that the higher dose of the drug met the...
21:26 , Jun 13, 2018 |  BC Extra  |  Clinical News

Lilly planning Phase III trials for Olumiant in lupus

Eli Lilly and Co. (NYSE:LLY) said it plans to start this year Phase III testing of Olumiant baricitinib to treat systemic lupus erythematosus (SLE) after reporting that the higher dose of the drug met the...
18:29 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

FDA approves Lilly's Olumiant for RA

FDA approved Olumiant baricitinib from Eli Lilly and Co. (NYSE:LLY) and partner Incyte Corp. (NASDAQ:INCY) to treat moderate to severe rheumatoid arthritis in patients who have responded poorly to one or more TNF antagonists. Lilly intends...
19:06 , Jun 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Thrombosis Mouse studies suggest JAK inhibitors could help treat thrombosis in patients with JAK-2 mutations. In a mouse model of deep vein stenosis-induced thrombosis harboring a gain-of-function JAK-2 mutation, the JAK-1/JAK-2 inhibitor Jakafi ruxolitinib decreased...
16:32 , Jun 6, 2018 |  BC Innovations  |  Translation in Brief

JAKs and clots

Brigham and Women’s Hospital researchers have uncovered the mechanisms behind a major complication in bone marrow disorders by linking a JAK-2 mutation with thrombosis in patients and mice, and identified a way to treat blood...
17:02 , Jun 1, 2018 |  BC Extra  |  Company News

FDA approves Lilly's Olumiant for RA

FDA approved Olumiant baricitinib from Eli Lilly and Co. (NYSE:LLY) and partner Incyte Corp. (NASDAQ:INCY) to treat moderate to severe rheumatoid arthritis in patients who have responded poorly to one or more TNF antagonists. Lilly intends...
19:29 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

FDA committee split on Olumiant dosing

FDA's Arthritis Advisory Committee voted on April 23 in favor of approving a once-daily 2 mg dose of rheumatoid arthritis candidate Olumiant baricitinib from Eli Lilly and Co. (NYSE:LLY) and partner Incyte Corp. (NASDAQ:INCY) but...